Literature DB >> 19098682

Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease.

Niksa Turk1, Silvija Cukovic-Cavka, Mirko Korsic, Zdenka Turk, Boris Vucelic.   

Abstract

OBJECTIVES: The high incidence of bone disease and the increasing evidence of Crohn's disease (CD) bone decline in corticosteroid users and nonusers suggest that bone metabolism is affected by inflammatory process. The aim of the study was to compare serum levels of proinflammatory cytokines, markers of bone turnover and regulatory molecules of osteoclast biogenesis, receptor activator of nuclear factor kappaB-ligand (RANKL) and osteoprotegerin (OPG), between naïve and long-standing CD patients.
METHODS: The study included 95 CD patients, 15 of them with newly diagnosed and previously untreated CD. The spine and hip bone mineral density was measured by dual-energy X-ray absorptiometry. Biochemical markers were determined by immunoassay.
RESULTS: Osteopenia was recorded at diagnosis in 53% of naïve patients and osteoporosis was found in 26% of long-standing CD patients. The newly diagnosed patients showed correlation between TNF-alpha and soluble RANKL (sRANKL) (r=0.5; P=0.04), and this positive relationship characterized the study population as a whole (r=0.3; P=0.003). Analysis of the OPG and sRANKL relationship showed absence of correlation in patients with healthy skeleton, whereas an inverse correlation was found in those with osteopenia (r=-0.31; P=0.033) and osteoporosis (r=-0.48; P=0.028). In naïve patients with reduced T score, the correlation between sRANKL and OPG was highly inverse (r=-0.8; P=0.02) and these patients were characterized by lower BMI, significantly higher level of proinflammatory cytokines, elevated C-reactive protein, and increased activity of free sRANKL and OPG.
CONCLUSION: Bone disease that accompanies CD at diagnosis suggests that bone metabolism is affected by the underlying inflammatory process per se, as probably confirmed by our finding of the central proinflammatory cytokine TNF-alpha being strongly associated with the osteoclastogenic mediator RANKL, and inversely with bone density.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19098682     DOI: 10.1097/MEG.0b013e3283200032

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  16 in total

Review 1.  Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases.

Authors:  Fayez K Ghishan; Pawel R Kiela
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-11-18       Impact factor: 4.052

2.  Use of dual energy X-ray absorptiometry in pediatric patients.

Authors:  Halley Wasserman; Jennifer M O'Donnell; Catherine M Gordon
Journal:  Bone       Date:  2016-12-15       Impact factor: 4.398

Review 3.  Clinical relevance of changes in bone metabolism in inflammatory bowel disease.

Authors:  Pal Miheller; Katalin Lorinczy; Peter-Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

4.  Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children.

Authors:  Anna Wasilewska; Agnieszka Rybi-Szuminska; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2010-07-04       Impact factor: 3.714

5.  Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients.

Authors:  Federico Biscetti; Giuseppe Straface; Silvia Giovannini; Angelo Santoliquido; Flavia Angelini; Luca Santoro; Carlo Filippo Porreca; Giovanni Pecorini; Giovanni Ghirlanda; Andrea Flex
Journal:  Hum Genet       Date:  2012-09-11       Impact factor: 4.132

Review 6.  Risk factors for osteoporosis in inflammatory bowel disease patients.

Authors:  Carla Andrade Lima; Andre Castro Lyra; Raquel Rocha; Genoile Oliveira Santana
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

7.  Association between osteoprotegerin gene polymorphisms and cardiovascular disease in type 2 diabetic patients.

Authors:  Changlei Guo; Fudong Hu; Shaoli Zhang; Yakun Wang; Hengdao Liu
Journal:  Genet Mol Biol       Date:  2013-05-17       Impact factor: 1.771

8.  Low bone mineral density in Greek patients with inflammatory bowel disease: prevalence and risk factors.

Authors:  Ioannis E Koutroubakis; Christos Zavos; John Damilakis; Georgios Z Papadakis; John Neratzoulakis; Nikolaos Karkavitsas; Elias A Kouroumalis
Journal:  Ann Gastroenterol       Date:  2011

9.  Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn's disease.

Authors:  Carsten Posovszky; Veronika Pfalzer; Georgia Lahr; Jan Hendrik Niess; Jochen Klaus; Benjamin Mayer; Klaus-Michael Debatin; Georg B T von Boyen
Journal:  BMC Gastroenterol       Date:  2013-05-02       Impact factor: 3.067

Review 10.  Flavonoid intake and bone health.

Authors:  Connie M Weaver; D Lee Alekel; Wendy E Ward; Martin J Ronis
Journal:  J Nutr Gerontol Geriatr       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.